The results from this study could provide insight into the effects of the mechanism of action of AKR1B1 inhibition on cancer and contribute data for further clinical use in the treatment of breast and ovarian cancers with aggressive migration and, thus, provide a new opportunity for chemotherapeutic agent combinations. This evidence concerns the gene AKR1B1 and ovarian cancer.